DESIGNED TO BE DIFFERENT
by minimising off-target effects in the treatment of B-cell malignancies19–22
Proven efficacy regardless of line of
therapy, genetic status and patient
populations23–27
A consistent safety profile
demonstrated across B-cell
malignancies for over five years1,27–29
Unmatched BTK inhibitor
dosing flexibility1,30,31